AMRX — Amneal Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.17bn
- $7.69bn
- $3.02bn
U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities
U.S. STOCKS ON THE MOVE- Twilio, Bath & Body Works, Wingstop
U.S. STOCKS ON THE MOVE-Nike, Domino's Pizza, Apple
Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT
U.S. RESEARCH ROUNDUP-Amneal pharma, Aramark, Bluebird Bio
Brief: Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide
Teva loses US appeal to keep inhaler patents on FDA protected drug list (updated)
Teva loses US appeal to keep inhaler patents on FDA protected drug list
Brief: Amneal Resubmits DHE Autoinjector New Drug Application And Receives U.S. FDA Approval Of Exenatide
Amneal Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Amneal Reports Third Quarter 2024 Financial Results
U.S. STOCKS ON THE MOVE-3M, VF Corp, SiriusXM
U.S. STOCKS ON THE MOVE-Howmet Aerospace, Alaska Air, Arcus Biosciences
Brief: Amneal Receives U.S. FDA Approval Of New Drug Application For Pyridostigmine Bromide Extended-Release Tablets
Amneal rises as US FDA approves pretreatment for nerve agent poisoning
Amneal asks court to block Colorado's free allergy pen program
Brief: Amneal Launches Crexont® (Carbidopa And Levodopa) Extended-Release Capsules For Treatment Of Parkinson’S Disease
U.S. STOCKS ON THE MOVE-Stericycle, Oil companies, US Banks
U.S. STOCKS ON THE MOVE-DocuSign, U.S homebuilders, Texas Capital Bancshares